NBIX•benzinga•
Piper Sandler Reiterates Overweight on Neurocrine Biosciences, Maintains $160 Price Target
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 23, 2024 by benzinga